Evidence map›Paper›PMID 37626376›Full record

ReviewVirology journal2023

A study on the effect of natural products against the transmission of B.1.1.529 Omicron.

Samar Sami Alkafaas, Abanoub Mosaad Abdallah, Aya Misbah Hussien, Heba Bedair, Mahmoud Abdo, Soumya Ghosh, Sara Samy Elkafas, Wilgince Apollon, Morteza Saki, Samah A Loutfy and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Virology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 5 countries.

Samar Sami AlkafaasMolecular Cell Biology Unit, Division of Biochemistry, Department of Chemistry, Faculty of Science, Tanta University, Tanta, 31527, Egypt. samar.alkafas@science.tanta.edu.eg.
Abanoub Mosaad AbdallahNarcotic Research Department, National Center for Social and Criminological Research (NCSCR), Giza, 11561, Egypt.
Aya Misbah HussienBiotechnology Department at Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.
Heba BedairBotany Department, Faculty of Science, Tanta University, Tanta, Egypt.
Mahmoud AbdoDivision of Biochemistry, Department of Chemistry, Faculty of Science, Tanta University, Tanta, 31527, Egypt.
Soumya GhoshDepartment of Genetics, Faculty of Natural and Agricultural Sciences, University of the Free State, Bloemfontein, 9301, South Africa. GhoshS@ufs.ac.za.
Sara Samy ElkafasProduction Engineering and Mechanical Design Department, Faculty of Engineering, Menofia University, Menofia, Egypt.
Wilgince ApollonDepartment of Agricultural and Food Engineering, Faculty of Agronomy, Universidad Autónoma de Nuevo León, Francisco Villa S/N, Ex-Hacienda El Canadá, 66050, General Escobedo, Nuevo León, Mexico.
Morteza SakiDepartment of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Samah A LoutfyVirology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Helen OnyeakaSchool of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. h.onyeaka@bham.ac.uk.
Mohamed HessienMolecular Cell Biology Unit, Division of Biochemistry, Department of Chemistry, Faculty of Science, Tanta University, Tanta, 31527, Egypt.
Tanta University · EGAhvaz Jundishapur University of Medical Sciences · IRAl-Ahram Center for Political and Strategic Studies · EGAlexandria University · EGCairo University · EGMenoufia University · EGUniversidad Autónoma de Nuevo León · MXUniversity of Birmingham · GBUniversity of the Free State · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe recent outbreak of the Coronavirus pandemic resulted in a successful vaccination program launched by the World Health Organization. However, a large population is still unvaccinated, leading to the emergence of mutated strains like alpha, beta, delta, and B.1.1.529 (Omicron). Recent reports from the World Health Organization raised concerns about the Omicron variant, which emerged in South Africa during a surge in COVID-19 cases in November 2021. Vaccines are not proven completely effective or safe against Omicron, leading to clinical trials for combating infection by the mutated virus. The absence of suitable pharmaceuticals has led scientists and clinicians to search for alternative and supplementary therapies, including dietary patterns, to reduce the effect of mutated strains. MAIN BODY: This review analyzed Coronavirus aetiology, epidemiology, and natural products for combating Omicron. Although the literature search did not include keywords related to in silico or computational research, in silico investigations were emphasized in this study. Molecular docking was implemented to compare the interaction between natural products and Chloroquine with the ACE2 receptor protein amino acid residues of Omicron. The global Omicron infection proceeding SARS-CoV-2 vaccination was also elucidated. The docking results suggest that DGCG may bind to the ACE2 receptor three times more effectively than standard chloroquine.

conclusionThe emergence of the Omicron variant has highlighted the need for alternative therapies to reduce the impact of mutated strains. The current review suggests that natural products such as DGCG may be effective in binding to the ACE2 receptor and combating the Omicron variant, however, further research is required to validate the results of this study and explore the potential of natural products to mitigate COVID-19.

Indexed as

Biological ProductsCOVID-19Angiotensin-Converting Enzyme 2ChloroquineCOVID-19 Drug TreatmentCOVID-19 VaccinesHumansMolecular Docking SimulationSARS-CoV-2Angiotensin-Converting Enzyme 2Biological ProductsChloroquineCOVID-19 VaccinesCOVID-19In silicoMolecular dockingNatural productOmicronVaccine

Identifiers

PMID37626376
PMCPMC10464336
OpenAlexW4386164327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.